Schonfeld Strategic Advisors’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-75,238
| Closed | -$278K | – | 2349 |
|
|
2025
Q4 | $278K | Buy |
+75,238
| New | +$243K | ﹤0.01% | 1597 |
|
|
2024
Q4 | – | Sell |
-518,100
| Closed | -$855K | – | 2117 |
|
|
2024
Q3 | $855K | Sell |
518,100
-329,627
| -39% | -$666K | 0.01% | 1212 |
|
|
2024
Q2 | $1.88M | Sell |
847,727
-99,779
| -11% | -$235K | 0.01% | 935 |
|
|
2024
Q1 | $2.54M | Sell |
947,506
-143,822
| -13% | -$349K | 0.02% | 905 |
|
|
2023
Q4 | $3.26M | Sell |
1,091,328
-140,499
| -11% | -$182K | 0.02% | 641 |
|
|
2023
Q3 | $1.21M | Sell |
1,231,827
-84,273
| -6% | -$122K | 0.01% | 963 |
|
|
2023
Q2 | $1.83M | Sell |
1,316,100
-493,811
| -27% | -$690K | 0.02% | 777 |
|
|
2023
Q1 | $2.88M | Buy |
1,809,911
+1,102,859
| +156% | +$5.69M | 0.03% | 597 |
|
|
2022
Q4 | $4.4M | Sell |
707,052
-96,017
| -12% | -$687K | 0.04% | 513 |
|
|
2022
Q3 | $5.38M | Buy |
803,069
+743,069
| +1,238% | +$5.1M | 0.05% | 509 |
|
|
2022
Q2 | $382K | Sell |
60,000
-46,900
| -44% | -$266K | ﹤0.01% | 1523 |
|
|
2022
Q1 | $496K | Sell |
106,900
-183,400
| -63% | -$787K | ﹤0.01% | 1377 |
|
|
2021
Q4 | $1.45M | Buy |
290,300
+276,543
| +2,010% | +$2.21M | 0.01% | 793 |
|
|
2021
Q3 | $166K | Sell |
13,757
-46,308
| -77% | -$674K | ﹤0.01% | 1819 |
|
|
2021
Q2 | $1.27M | Buy |
+60,065
| New | +$1.45M | 0.01% | 857 |
|
|
2019
Q4 | – | Sell |
-182,019
| Closed | -$6.67M | – | 1345 |
|
|
2019
Q3 | $6.67M | Buy |
+182,019
| New | +$7.21M | 0.2% | 136 |
|
|
2018
Q1 | – | Sell |
-3,265
| Closed | -$215K | – | 823 |
|
|
2017
Q4 | $215K | Buy |
+3,265
| New | +$176K | 0.02% | 661 |
|
|
2016
Q4 | – | Sell |
-20,062
| Closed | -$278K | – | 575 |
|
|
2016
Q3 | $278K | Buy |
+20,062
| New | +$227K | 0.05% | 323 |
|
Other funds holding ESPR
WA
TSC
O
VCM
